Contravir Pharmaceuticals Inc., of Edison, N.J., said new studies of its hepatitis B virus-optimized cyclophilin inhibitor CRV431 show that it blocks the interaction between hepatitis B surface antigen (HBsAg), a key HBV protein, and cyclophilin A, an important cellular protein.